Advancing Personalized Breast Cancer Vaccine with Multiepitope Antigens and Biomimetic Nanoparticles

KLH-GP2-P4 peptide, derived from HER2 receptor of breast cancer tumor, serves as tumor-associated antigen in breast cancer vaccines (2). Cancer cell membrane (CCM) coating on vaccine formulation enhances immune recognition by mimicking native tumor antigens and providing more  potent tumor-specific antigens (1). In this study, liposomes (LP) loaded with KLH-GP2-P4 are coated with CCM derived from either TUBO or 4T1 cells. We evaluate how different CCM sources influence vaccine specificity and personalization, providing insights into tailored cancer immunotherapy with biomimetic nanoparticles.